AngioSoma, Inc. (OTCQB:SOAN) released an updated shareholder presentation this week summarizing the company's activity over the last two months. Next week an audio discussion in a " fireside chat" format between Chairman Emeritus David P. Summers Ph.D. and CEO Alexanderia Blankenship will be released that will provide further details on a slide by slide basis. The presentation is available on our newly revised website's home page ( http://angiosoma.info), directly at http://angiosoma.info/shareholder-presentation-november-2016, and on the OTC Markets' website at http://www.otcmarkets.com/stock/SOAN/video-and-presentations. Please note the Company's website properties have increased to accommodate greater information for shareholders and prospective investors alike. Our web properties include: http://angiosoma.infohttp://angiosoma.comhttp://angiosoma.net http://liprostin.com ABOUT ANGIOSOMA, INC. AngioSoma, Inc. (OTCQB:SOAN, http://angiosoma.info) is a clinical stage biotechnology company focused on improving the effectiveness of current standard-of-care treatments related to pharmaceutical or endovascular interventions. Our " end to end" solution will provide interventional radiologists, cardiologists, and internal medicine physicians with both pharmaceutical and/or endovascular interventional options prior to infarction or critical limb ischemic events, stabilizing or reversing the atherosclerotic disease. Our Soma Nutraceutical Inc. subsidiary aims to provide dietary anti-inflammatory, blood thinning, and anti-clotting natural products, as either stand alone or adjuncts to pharmaceutical care. For pharmaceutical stabilization, our Liprostin™ product for treatment of peripheral artery disease (" PAD") completed preliminary U.S. Food and Drug Administration (" FDA") required Phase I and Phase II clinical trials successfully and is entering Phase III prior to approval. Our AngioSoma Research, Inc. subsidiary also owns the OmniCath I & II plaque debulking and vessel remodeling atherectomy catheter which will further support the stabilization of patients experiencing infarction or critical limb ischemic symptoms. For long-term preventative measures, our Transdermal PGE-1 Patch will provide ongoing treatment for chronic cardiovascular disease by delivery of PGE-1 or Liprostin™ through the skin.